Treatment for OHT or suspected COAG
| CCT | More than 590 µm | 555–590 µm | Less than 555 µm | Any | |||
|---|---|---|---|---|---|---|---|
| Untreated IOP (mm Hg) | >21–25 | >25–32 | >21–25 | >25–32 | >21–25 | >25–32 | >32 |
| Age (years)* | Any | Any | Any | Treat until 60 | Until 65 | Until 80 | Any |
| Treatment | No treatment | No treatment | No treatment | BB† | PGA | PGA | PGA |
*Treatment should not be routinely offered to people over the age threshold unless there are likely to be benefits from the treatment over an appropriate timescale. Once a person being treated for OHT reaches the age threshold for stopping treatment but has not developed COAG, healthcare professionals should discuss the option of stopping treatment. The use of age thresholds is considered appropriate only where vision is currently normal (OHT with or without suspicion of COAG) and the treatment is purely preventative. Under such circumstances the threat to a person's sighted lifetime is considered negligible. In the event of COAG developing in such a person treatment is recommended.
†If BBs are contraindicated offer a PGA.
BB, β blocker; CCT, central corneal thickness; COAG, chronic open-angle glaucoma; IOP, intraocular pressure; OHT, ocular hypertension; PGA, prostaglandin analogue.